OrbiMed’s Arcutis Biotherapeutics ARQT Stock Holding History

OrbiMed’s Portfolio ARQT Stock Details ARQT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$53.5M	Buy	+2,042,000	New	+$47.6M	0.99%	32
2023 Q4	–	Sell	-1,914,479	Closed	-$10.2M	–	115
2023 Q3	$10.2M	Hold	1,914,479	–	–	0.22%	84
2023 Q2	$18.2M	Hold	1,914,479	–	–	0.33%	72
2023 Q1	$21.1M	Sell	1,914,479 -545,629	-22%	-$7.89M	0.41%	64
2022 Q4	$36.4M	Sell	2,460,108 -339,892	-12%	-$5.94M	0.7%	52
2022 Q3	$53.5M	Sell	2,800,000 -1,981,646	-41%	-$44.9M	0.99%	36
2022 Q2	$102M	Sell	4,781,646 -1,292,204	-21%	-$26.5M	1.85%	19
2022 Q1	$117M	Hold	6,073,850	–	–	1.9%	18
2021 Q4	$126M	Hold	6,073,850	–	–	1.62%	20
2021 Q3	$145M	Hold	6,073,850	–	–	1.59%	19
2021 Q2	$166M	Hold	6,073,850	–	–	1.68%	16
2021 Q1	$176M	Hold	6,073,850	–	–	1.64%	17
2020 Q4	$171M	Buy	6,073,850 +1,400,000	+30%	+$34.3M	1.5%	17
2020 Q3	$137M	Hold	4,673,850	–	–	1.72%	17
2020 Q2	$141M	Hold	4,673,850	–	–	1.99%	19
2020 Q1	$139M	Buy	+4,673,850	New	+$126M	2.34%	12

Other funds holding ARQT

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

OrbiMed's ARQT Position: Q2 2026 in Review

OrbiMed opened a new position in Arcutis Biotherapeutics (ARQT) in Q2 2026: 2,042,000 shares worth $53.5M. The stake represents 0.99% of the portfolio and ranks #32 among its holdings. This is a return to the name: OrbiMed previously reported a position in ARQT as recently as Q3 2023.

OrbiMed first reported a position in ARQT in Q1 2020 and has held it in 16 quarters since. The position peaked at $176M in Q1 2021. 273 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

OrbiMed held 2,042,000 shares of Arcutis Biotherapeutics worth $53.5M as of Q2 2026.
Arcutis Biotherapeutics was a new OrbiMed position in Q2 2026.
Arcutis Biotherapeutics made up 0.99% of OrbiMed's portfolio in Q2 2026, its #32 holding.
OrbiMed first reported a position in Arcutis Biotherapeutics in Q1 2020 and has held it in 16 quarters since.
OrbiMed's Arcutis Biotherapeutics position peaked at $176M in Q1 2021.
273 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on OrbiMed's 13F filing for Q2 2026, filed 14 Aug 2026.